Targeting interleukin-21 in immune-mediated pathologies

Current Drug Targets

Volumn 11, Issue 5, 2010, Pages 645-649

  Sarra, Massimiliano ^a   Pallone, Francesco ^a   Macdonald, Thomas T ^b   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Atopic dermatitis; Diabetes; IBD; IL 21; Lupus; Rheumatoid arthritis

Indexed keywords

CHEMOKINE; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 21; INTERLEUKIN 21 INHIBITOR; PROTEINASE; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG TARGETING; EPITHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFLAMMATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKINS; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN-21;

EID: 77951081159     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791011910     Document Type: Review

References (47)

1. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408(6808): 57-63.
2. Spolski R, Leonard WJ. Interleukin-21. Basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26: 57-79.
3. Intlekofer AM, Banerjee A, Takemoto N, et al. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 2008; 321(5887): 408-411 (Pubitemid 352029977)
4. Coquet JM, Kyparissoudis K, Pellicci DG, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007; 178(5): 2827-2834 (Pubitemid 46333160)
5. Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008; 29(1): 127-137
6. Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008; 454(7202): 350-352
7. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8(9): 967-974 (Pubitemid 47300011)
8. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448(7152): 484-487 (Pubitemid 47123515)
9. Suto A, Kashiwakuma D, Kagami S, et al. Development and characterization of IL-21-producing CD4+ T cells. J Exp Med 2008; 205(6): 1369-1379 (Pubitemid 351831493)
10. Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001; 167(1): 1-5. (Pubitemid 32567752)
11. Monteleone G, Pallone F, MacDonald TT. Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol 2008; 29(6): 290-294
12. Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008; 20(3): 295-301. (Pubitemid 351600371)
13. Nurieva RI, Chung Y, Martinez GJ, et al. BCL-6 mediates the development of T follicular helper cells. Science 2009; 325(5943): 1001-1005
14. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008; 134(4): 1038-1048 (Pubitemid 351451986)
15. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117(2): 265-277 (Pubitemid 38496245)
16. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci USA 2008; 105(37): 14028-14033
17. Sutherland AP, Van Belle T, Wurster AL, et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009; 58(5): 1144-1155
18. Jin H, Oyoshi MK, Le Y, et al. IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J Clin Invest 2009; 119(1): 47-60.
19. Bubier JA, Sproule TJ, Foreman O, et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci USA 2009; 106(5): 1518-1523
20. Bubier JA, Bennett SM, Sproule TJ, et al. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1110: 590-601.
21. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007; 178(6): 3822-3830 (Pubitemid 46417651)
22. Vinuesa CG, Cook MC, Angelucci C, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005; 435(7041): 452-458 (Pubitemid 40734237)
23. Young DA, Hegen M, Ma HL, et al. Blockade of the interleukin-21/ interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007; 56(4): 1152-1163 (Pubitemid 46608640)
24. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 2005; 174(5): 2696-2701 (Pubitemid 40279684)
25. Sonderegger I, Kisielow J, Meier R, King C, Kopf M. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur J Immunol 2008; 38(7): 1833-1838
26. Piao WH, Jee YH, Liu RL, et al. IL-21 modulates CD4+ CD25+ regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. Scand J Immunol 2008; 67(1): 37-46.
27. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005; 128(3): 687-694 (Pubitemid 40585371)
28. Monteleone G, Caruso R, Fina D, et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006; 55(12): 1774-1780 (Pubitemid 44893577)
29. Caruso R, Fina D, Peluso I, et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007; 132(1): 166-175 (Pubitemid 46108732)
30. Caruso R, Fina D, Peluso I, et al. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol 2007; 178(9): 5957-5965 (Pubitemid 46674393)
31. Fina D, Sarra M, Caruso R, et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 2008; 57(7): 887-892 (Pubitemid 351919521)
32. Distler JH, Jüngel A, Kowal-Bielecka O, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005; 52(3): 856-864 (Pubitemid 40365109)
33. Jüngel A, Distler JH, Kurowska-Stolarska M, et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004; 50(5): 1468-1476 (Pubitemid 38608068)
34. Andersson AK, Feldmann M, Brennan FM. Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand J Immunol 2008; 68(1): 103-111 (Pubitemid 351798402)
35. Van Heel DA, Franke L, Hunt KA, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007; 39(7): 827-829 (Pubitemid 47014494)
36. Festen EA, Goyette P, Scott R, et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009; 58(6): 799-804.
37. Asano K, Ikegami H, Fujisawa T, et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum Immunol 2007; 68(5): 384-391 (Pubitemid 46616978)
38. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4(3): e1000041. (Pubitemid 351656703)
39. Chatterjee R, Batra J, Ghosh B. A common exonic variant of interleukin21 confers susceptibility to atopic asthma. Int Arch Allergy Immunol 2009; 148(2): 137-146
40. Sawalha AH, Kaufman KM, Kelly JA, et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008; 67(4): 458-461 (Pubitemid 351498423)
41. Hecker M, Bohnert A, König IR, Bein G, Hackstein H. Novel genetic variation of human interleukin-21 receptor is associated with elevated IgE levels in females. Genes Immun 2003; 4(3): 228-233 (Pubitemid 38967601)
42. Khoruts A, Fraser JM. A causal link between lymphopenia and autoimmunity. Immunol Lett 2005; 98(1): 23-31.
43. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119(7): 2052-2061
44. Brandt K, Bulfone-Paus S, Foster DC, Rückert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003; 102(12): 4090-4098 (Pubitemid 37486993)
45. Spolski R, Kim HP, Zhu W, Levy DE, Leonard WJ. IL-21 mediates suppressive effects via its induction of IL-10. J Immunol 2009; 182(5): 2859-2867
46. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 2009; 324(5934): 1569-1572
47. Andorsky DJ, Timmerman JM. Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther 2008; 8 (9):1295-1307